Condition: Gastric Cancer Stage IV · Peritoneal Metastases From Gastric Cancer · Gastric or Esophagogastric Junction Adenocarcinoma · Sponsor: Ruijin Hospital
In this study, the investigators will use LM-302 and S-1 plus intraperitoneal paclitaxel with or without Cadonilimab to treat Claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis.
This description comes directly from the study's public registry record.
Zhongyin Yang · 8621-64370045 · jeffreyyong@163.com
Always discuss trial participation with your own doctor first.
| Ruijin Hospital Shanghai Jiao Tong University School of Medicine | Shanghai, Huangpu District, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07556640